NeuroSense receives Japanese patent for ALS drug candidate PrimeC

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that the Japan Patent Office has issued Japanese Patent 7857044 covering the company's lead drug candidate PrimeC for treating amyotrophic lateral sclerosis.

The patent, titled "Compositions comprising ciprofloxacin and celecoxib," includes 17 claims and provides protection through 2042 for PrimeC's formulation and manufacturing process. The patent covers the synchronized delivery profile of celecoxib and ciprofloxacin, which targets multiple mechanisms underlying ALS progression.

"This patent grant further strengthens our global intellectual property estate around PrimeC and reinforces the novelty of our synchronized extended-release formulation," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "Japan is a key pharmaceutical market, and this patent further supports our long-term commercialization strategy as we advance PrimeC toward a pivotal Phase 3 clinical trial."

The Japanese patent adds to NeuroSense's global intellectual property portfolio, which already includes patents in the United States, Australia and Brazil. PrimeC is designed to modulate neuroinflammation, iron dysregulation, autophagy, and miRNA pathways.

The company reported that PrimeC demonstrated clinical, biomarker, and survival benefits in its Phase 2b PARADIGM study. NeuroSense has received FDA clearance to proceed with a Phase 3 pivotal study called PARAGON.

PrimeC is an extended-release oral formulation combining ciprofloxacin and celecoxib, both previously FDA-approved drugs. The combination targets several mechanisms that contribute to neuron degeneration in ALS and Alzheimer's disease.

ALS is a neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. More than 5,000 people are diagnosed with ALS annually in the United States, with an annual disease burden of $1 billion.

You May Also Be Interested In

• NVIDIA, Mitsubishi Heavy Industries eye cooperation on AI data center cooling and power - Nikkei
• Kyndryl and Aptiv announce strategic collaboration
• Acorn Capital sells Berry Aviation to Bristow Group